These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14644934)

  • 1. What do we gain from the sixth coronary heart disease drug?
    Warburton RN
    BMJ; 2003 Nov; 327(7426):1237-8. PubMed ID: 14644934
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enthusiasm, reality, and cost-effectiveness analysis.
    Brophy JM; Sleight P
    Heart; 1998 Jan; 79(1):9-10. PubMed ID: 9505910
    [No Abstract]   [Full Text] [Related]  

  • 4. PCI and stable coronary heart disease--COURAGE to change our minds?
    Kakafika AI; Mikhailidis DP; Wierzbicki AS; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2007 Jul; 5(3):173-4. PubMed ID: 17627560
    [No Abstract]   [Full Text] [Related]  

  • 5. When increased therapeutic benefit comes at increased cost.
    Wood AJ
    N Engl J Med; 2002 Jun; 346(23):1819-21. PubMed ID: 12050345
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.
    Spahillari A; Zhu J; Ferket BS; Hunink MGM; Carr JJ; Terry JG; Nelson C; Mwasongwe S; Mentz RJ; O'Brien EC; Correa A; Shah RV; Murthy VL; Pandya A
    JAMA Cardiol; 2020 Aug; 5(8):871-880. PubMed ID: 32401264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of accepted measures for intervention in coronary heart disease.
    Kuntz KM; Lee TH
    Coron Artery Dis; 1995 Jun; 6(6):472-8. PubMed ID: 7551268
    [No Abstract]   [Full Text] [Related]  

  • 9. The value of coronary heart disease care for the elderly: 1987-2002.
    Rosen AB; Cutler DM; Norton DM; Hu HM; Vijan S
    Health Aff (Millwood); 2007; 26(1):111-23. PubMed ID: 17211020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial.
    Vieira RD; Hueb W; Hlatky M; Favarato D; Rezende PC; Garzillo CL; Lima EG; Soares PR; Hueb AC; Pereira AC; Ramires JA; Kalil Filho R
    Circulation; 2012 Sep; 126(11 Suppl 1):S145-50. PubMed ID: 22965975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of organic nitrates in therapy of coronary heart disease in terms of clinical cost-effectiveness].
    Solianik EV; Beliaeva LA; Gel'tser BI
    Klin Med (Mosk); 2002; 80(12):4-9. PubMed ID: 12638402
    [No Abstract]   [Full Text] [Related]  

  • 13. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 15. Methods and mindsets in pharmacoeconomics.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S213-5. PubMed ID: 10184935
    [No Abstract]   [Full Text] [Related]  

  • 16. [Heart catheter in stable coronary heart disease. Drugs are equally effective].
    Einecke D
    MMW Fortschr Med; 2007 Apr; 149(15):10, 12. PubMed ID: 17668771
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.
    Rosen VM; Taylor DC; Parekh H; Pandya A; Thompson D; Kuznik A; Waters DD; Drummond M; Weinstein MC
    Pharmacoeconomics; 2010; 28(1):47-60. PubMed ID: 20014876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dollars and sense of drug-eluting stents.
    Brophy JM
    CMAJ; 2005 Feb; 172(3):361-2. PubMed ID: 15684119
    [No Abstract]   [Full Text] [Related]  

  • 19. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
    Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major risk factors and coronary heart disease: much has been achieved but crucial challenges remain.
    Daviglus ML; Stamler J
    J Am Coll Cardiol; 2001 Oct; 38(4):1018-22. PubMed ID: 11583875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.